[Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)]
| Autor: | Efraín, Díaz-Jouanen, Carlos, Abud-Mendoza, Mario Alberto, Garza-Elizondo, Gabriel, Medrano-Ramírez, Rubén, Burgos-Vargas, José Javier, Orozco-Alcalá, César Francisco, Pacheco-Tena, Carlos, Pineda, Juan Carlos, Pozos-Espíndola, Francisco, Ramos-Niembro, Manuel, Robles-San-Román, Jesús Ernesto, Santana-Sahagún |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Risk Clinical Trials as Topic Tumor Necrosis Factor-alpha Anti-Inflammatory Agents Non-Steroidal Communicable Diseases Arthritis Juvenile Lymphoproliferative Disorders Arthritis Rheumatoid Pregnancy Complications Cardiovascular Diseases Pregnancy Antirheumatic Agents Neoplasms Preoperative Care Humans Lactation Female Immunization Child Immunosuppressive Agents |
| Zdroj: | Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion. 61(3) |
| ISSN: | 0034-8376 |
| Popis: | Recommendations for the use of Disease-Modifying Antirheumatic Drugs (DMARD) with both conventional and biological agents in Rheumatoid Arthritis (RA) must be based on their safety profile, adverse effects, risks, and advantages. With the purpose of presenting the most updated information about the safety of tumor necrosis factor alpha (TNFalpha) antagonists, in this article we summarize the literature published during the last three years about this sort of biological agents in specific clinical situations, such as risk of developing infections, cancer, cardiovascular diseases, and autoimmunity; as well as their administration to patients who will undergo surgical procedures, pregnant and/or breast-feeding women, and patients who need immunizations. Likewise, in this analysis we offer specific recommendations, based on evidence, for the best anti-TNF-alfa management. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|